Found: 13
Select item for more details and to access through your institution.
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
- Published in:
- Neuro-Oncology, 2018, v. 20, n. 6, p. 838, doi. 10.1093/neuonc/nox202
- By:
- Publication type:
- Article
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
- Published in:
- Neuro-Oncology, 2017, v. 19, n. 7, p. 965, doi. 10.1093/neuonc/now257
- By:
- Publication type:
- Article
Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2014, v. 13, n. 3, p. 156, doi. 10.1016/j.clcc.2014.04.001
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 2, p. 1, doi. 10.2967/jnumed.120.253146
- By:
- Publication type:
- Article
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
- Published in:
- 2018
- By:
- Publication type:
- journal article